Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.38 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187749 | 1.00 | NAMPT (0.41) | NAMPTSYKKDM4ETMPRSS2KCNA1 | |
| SCHEMBL1189690 | 0.91 | NAMPT (0.42) | NAMPTSYKTMPRSS2ROCK2 | |
| SCHEMBL1189686 | 0.91 | NAMPT (0.42) | NAMPTSYKTMPRSS2ROCK2 | |
| SCHEMBL1188003 | 0.90 | NPC1 (0.49) | NAMPTSYKKDM4EROCK2MEN1 | |
| SCHEMBL1188004 | 0.90 | NPC1 (0.49) | NAMPTSYKKDM4EROCK2MEN1 | |
| SCHEMBL1187722 | 0.89 | FPR2 (0.41) | NAMPTSYKKDM4ETMPRSS2KCNA1 | |
| SCHEMBL1187719 | 0.89 | FPR2 (0.41) | NAMPTSYKKDM4ETMPRSS2KCNA1 | |
| SCHEMBL1187898 | 0.89 | KDM4E (0.42) | NAMPTSYKKDM4EROCK2POLB | |
| SCHEMBL1187897 | 0.89 | KDM4E (0.42) | NAMPTSYKKDM4EROCK2POLB | |
| SCHEMBL1188550 | 0.88 | SYK (0.39) | NAMPTSYKKDM4ETMPRSS2KCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | NAMPT 934/4885SYK 4151/4885KDM4E 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.